RECRUITING

An Ophthalmic Safety Study in Patients With Breast Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To assess ophthalmic health in parallel cohorts of patients with breast cancer

Official Title

A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer

Quick Facts

Study Start:2025-03-04
Study Completion:2027-07-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06767462

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 130 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Signed informed consent in the qualifying study.
  2. 2. Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures.
  3. 3. Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study.
  4. 4. Meets all the eligibility criteria in the qualifying study
  1. 1. Patients not randomized and not receiving study assigned treatment in a qualifying study.
  2. 2. Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents.
  3. 3. Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements

Contacts and Locations

Study Contact

AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479
information.center@astrazeneca.com

Study Locations (Sites)

Research Site
La Jolla, California, 92093
United States
Research Site
Palo Alto, California, 94304
United States
Research Site
San Diego, California, 92123
United States
Research Site
Iowa City, Iowa, 52242
United States
Research Site
New York, New York, 10029
United States
Research Site
Winston-Salem, North Carolina, 27104
United States
Research Site
Cleveland, Ohio, 44195
United States
Research Site
Clairton, Pennsylvania, 15025
United States
Research Site
Pittsburgh, Pennsylvania, 15219
United States
Research Site
Sioux Falls, South Dakota, 57105
United States
Research Site
Bartlett, Tennessee, 38133
United States
Research Site
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: AstraZeneca

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-04
Study Completion Date2027-07-06

Study Record Updates

Study Start Date2025-03-04
Study Completion Date2027-07-06

Terms related to this study

Keywords Provided by Researchers

  • Ophthalmic Safety assessment

Additional Relevant MeSH Terms

  • Ophthalmic Safety in Patients With Breast Cancer